主动科技
Shanghai Active Technology, incubated by Lingang Laboratory and founded in 2026, develops invasive brain-computer interfaces with in-house flexible electrodes, dedicated chips, neural decoding algorithms and system integration across motor, visual and emotional product lines.
Position in SVTRnew
Snapshot 2026-11-04- Startup SignalsRankedof 2,311
- Life SciencesRankedof 244
- Medtech DeviceRankedof 47
- BCIRankedof 19
About
Shanghai Active Technology, incubated by Lingang Laboratory and founded in 2026, develops invasive brain-computer interfaces with in-house flexible electrodes, dedicated chips, neural decoding algorithms and system integration across motor, visual and emotional product lines. Its motor BCI system Tianshu obtained China's first type-test report for a 1024-channel invasive BCI system in November 2025.
Full tier & rationale — an SVTR Intelligence benefit
Capital graph
Funding history
- 2026-11-04Angel+$64M
Investors · Gaorong Ventures, 国投先导, 上海科创投, 康君资本, China Internet Investment Fund, 国泰海通, 浦东创投, 上海科创基金, 广药资本, 闵金投, Yunqi Partners, 道彤资本, 华大松禾, 英诺资本Source · news.pedaily.cn ↗
Comparable companies· by market
This company
BusinessLatest roundTotal raisedDate- 主动科技
Shanghai Active Technology, incubated by Lingang Laboratory and founded in 2026…
Angel · 2026-11
—
United States
BusinessLatest roundTotal raisedDate- Coherence Neuro
Closed-loop brain-computer interface system SOMA…
Series A · 2026-10
— - Nudge
Founded by Coinbase Co-founder Fred Ehrsam; develops non-invasive brain-computer interface devices
Series A · $100M · 2025-07
$100M - Axoft
Implantable brain-computer interfaces using biomimetic materials…
Series A · $60M · 2026-05
$60M
China
BusinessLatest roundTotal raisedDate- SiClink
Implantable brain-computer interfaces: in-house flexible neural electrodes and minimally invasive implantation with neural decoding/encoding algorithm…
— - NeuroXess
Implantable flexible brain-computer interface systems (neural signal acquisition chips + decoding algorithms) for patients with neurological disorders
Series B · 2026-10
— - BCI-Sonics
Non-invasive AI ultrasound brain-computer interface (transcranial focused ultrasound neuromodulation + multimodal brain reading and AI neural decoding…
Series A · $42M · 2026-09
$42M
Europe
BusinessLatest roundTotal raisedDate- MintNeuro
Imperial College London spinout developing composable chip modules for neural signal acquisition, electrical stimulation…
Undisclosed · 2026-10
— - Neurosoft Bioelectronics
Flexible, stretchable, non-penetrating brain-computer interfaces and neural electrodes to record/stimulate brain-surface activity
Seed · $20M · 2026-05
$20M - InBrain Neuroelectronics
Graphene-based brain-computer interface technology for neurological disorders such as Parkinson's disease.
Series B · $50M · 2024-11
$50M
Other / unspecified
BusinessLatest roundTotal raisedDate- 脑思科技
Brain-computer interface electrodes and neural decoding systems
Angel · $10M · 2026-05
$10M - Brain.space
Non-invasive brain monitoring platform with real-time neural data analysis
Series A · $11M · 2025-03
$11M - IMeditech
R&D and manufacturing of electrospun nanofiber wound care devices, vascular stents, catheters and neurointerventional devices…
$1.1B
$1.1B
Confirmed rounds only. Matched on subsector, sector, stage and funding scale — each verifiable on the company profiles.
Investors that may fit
Dimension Capital
10 Life Sciences deals in the last 24 months · 4 at a nearby stage · 1 in East China
Request intro →OrbiMed Advisors
9 Life Sciences deals in the last 24 months · 3 at a nearby stage · 4 in East China
Request intro →Qiming Venture Partners
9 Life Sciences deals in the last 24 months · 3 at a nearby stage · 7 in East China
Request intro →Lilly Asia Ventures
8 Life Sciences deals in the last 24 months · 2 at a nearby stage · 7 in East China
Request intro →HongShan
7 Life Sciences deals in the last 24 months · 5 at a nearby stage · 6 in East China
Request intro →Matrix Partners China
6 Life Sciences deals in the last 24 months · 4 at a nearby stage · 4 in East China
Request intro →Ranked by each firm’s deals in this sector over the last 24 months, weighted by nearby stage and shared geography. Indicative only — no rating judgment.